TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sedation vs. Intubation for Endovascular Stroke TreAtment
Brief Summary: Sedation vs Intubation for Endovascular Stroke TreAtment Trial (SIESTA) is a prospective, randomised controlled, monocentric, two-armed, comparative trial. Patients are randomized 1 : 1 to either non-intubated state or to intubated state for endovascular stroke treatment. Otherwise, no principal differences in intensive care treatment are intended, and standard operating procedures are applied to ensure uniform management decisions in fields such as ventilation, sedation, cardio-vascular and cerebral monitoring and management.


Options:
A: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
B: Arm Label: general anesthesia; Type: EXPERIMENTAL; Interventions: Drug: Etomidate, Drug: Succinylcholine, Drug: Propofol, Drug: Remifentanil | Arm Label: sedation; Type: EXPERIMENTAL; Interventions: Drug: Remifentanil, Drug: Lidocaine | Intervention Type: DRUG; Name: Etomidate; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Succinylcholine; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Remifentanil; Assigned to Arm(s): general anesthesia, sedation | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): sedation
C: Arm Label: Intubation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular recanalisation | Arm Label: No Intubation; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular recanalisation | Intervention Type: PROCEDURE; Name: Endovascular recanalisation; Assigned to Arm(s): Intubation, No Intubation
D: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comprehensive Cardiovascular Diseases (CVD) Risk Reduction Trial in Persons With Serious Mental Illness
Brief Summary: This study will determine whether a program where a health coach works with participants on heart healthy behaviors and treatment of risk factors is coordinated with primary care can reduce overall heart disease risk in people with serious mental illness.


Options:
A: Arm Label: Collaborative care; Type: EXPERIMENTAL; Interventions: Other: Collaborative care | Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Collaborative care; Assigned to Arm(s): Collaborative care | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: IDEAL intervention; Type: EXPERIMENTAL; Interventions: Other: IDEAL intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: IDEAL intervention; Assigned to Arm(s): IDEAL intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: valproate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: inositol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family-focused Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Interpersonal and Social Rhythms Therapy; Assigned to Arm(s): N/A
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Program of Aerobic and Resistance Exercises Combined in Patients With Cystic Fibrosis (CF) With Impaired Glucose Tolerance or Diabetes Related to CF Without Medication
Brief Summary: The objective of the investigators research program is to determine whether a combined exercise program (aerobic and resistance) improves abnormal glucose tolerance and diabetes control in CF patients. This program of exercises to increase strength and muscle endurance, exercise tolerance, will be assessed in a group of 12 CF patients with impaired glucose tolerance. The effect of exercise will be compared with a control group of 12 patients also glucose intolerant but do not participate in structured physical activity program. The duration of the exercise program will be 12 weeks and several measures (glucose tolerance, inflammatory profile, lung function, exercise capacity, muscle strength and endurance) will be conducted pre and post program to assess the program's impact .


Options:
A: Arm Label: GLP-1 Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GLP-1 | Arm Label: GIP Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GIP | Intervention Type: DRUG; Name: GLP-1; Assigned to Arm(s): GLP-1 Incretin Hormone | Intervention Type: DRUG; Name: GIP; Assigned to Arm(s): GIP Incretin Hormone
B: Arm Label: Exercise; Type: OTHER; Interventions: Other: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Repaglinide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: short-acting Insulin (Actrapid) | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: short-acting Insulin (Actrapid); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Program of Aerobic and Resistance Exercises Combined in Patients With Cystic Fibrosis (CF) With Impaired Glucose Tolerance or Diabetes Related to CF Without Medication
Brief Summary: The objective of the investigators research program is to determine whether a combined exercise program (aerobic and resistance) improves abnormal glucose tolerance and diabetes control in CF patients. This program of exercises to increase strength and muscle endurance, exercise tolerance, will be assessed in a group of 12 CF patients with impaired glucose tolerance. The effect of exercise will be compared with a control group of 12 patients also glucose intolerant but do not participate in structured physical activity program. The duration of the exercise program will be 12 weeks and several measures (glucose tolerance, inflammatory profile, lung function, exercise capacity, muscle strength and endurance) will be conducted pre and post program to assess the program's impact .


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Electrostimulation programme: using a cycloergometer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual sport activity | Intervention Type: BEHAVIORAL; Name: Electrostimulation programme: using a cycloergometer; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual sport activity; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
D: Arm Label: Exercise; Type: OTHER; Interventions: Other: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Program of Aerobic and Resistance Exercises Combined in Patients With Cystic Fibrosis (CF) With Impaired Glucose Tolerance or Diabetes Related to CF Without Medication
Brief Summary: The objective of the investigators research program is to determine whether a combined exercise program (aerobic and resistance) improves abnormal glucose tolerance and diabetes control in CF patients. This program of exercises to increase strength and muscle endurance, exercise tolerance, will be assessed in a group of 12 CF patients with impaired glucose tolerance. The effect of exercise will be compared with a control group of 12 patients also glucose intolerant but do not participate in structured physical activity program. The duration of the exercise program will be 12 weeks and several measures (glucose tolerance, inflammatory profile, lung function, exercise capacity, muscle strength and endurance) will be conducted pre and post program to assess the program's impact .


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Electrostimulation programme: using a cycloergometer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual sport activity | Intervention Type: BEHAVIORAL; Name: Electrostimulation programme: using a cycloergometer; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual sport activity; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Supervised aerobic training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supervised strength training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Unsupervised training; Assigned to Arm(s): N/A
C: Arm Label: Exercise; Type: OTHER; Interventions: Other: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: 1. Exercise testing and self drainage session; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: 2. Chest physiotherapy (CP) session; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest physiotherapy | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): 1. Exercise testing and self drainage session, 2. Chest physiotherapy (CP) session

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study
Brief Summary: Obese patients undergoing bariatric surgery warrant VTE prophylaxis because they are at high risk for developing a fatal pulmonary embolism or postthrombotic syndrome. However, a consensus does not exist on the most effective prophylactic approach.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): N/A
D: Arm Label: ENOXAPARIN 2 HOURS BEFORE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Arm Label: Enoxaparin 40 mg 12 hours before; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Intervention Type: DRUG; Name: Enoxaparin 40 mg 2 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before | Intervention Type: DRUG; Name: Enoxaparin 40 mg 12 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study
Brief Summary: Obese patients undergoing bariatric surgery warrant VTE prophylaxis because they are at high risk for developing a fatal pulmonary embolism or postthrombotic syndrome. However, a consensus does not exist on the most effective prophylactic approach.


Options:
A: Arm Label: Low-Dose LMWH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: High-Dose LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): High-Dose LMWH, Low-Dose LMWH
B: Arm Label: ENOXAPARIN 2 HOURS BEFORE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Arm Label: Enoxaparin 40 mg 12 hours before; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Intervention Type: DRUG; Name: Enoxaparin 40 mg 2 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before | Intervention Type: DRUG; Name: Enoxaparin 40 mg 12 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before
C: Arm Label: Group 1; Type: OTHER; Interventions: Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed | Arm Label: Group 2; Type: OTHER; Interventions: Drug: Group 2: control group with enoxaparin 40mg/d | Intervention Type: DRUG; Name: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Group 2: control group with enoxaparin 40mg/d; Assigned to Arm(s): Group 2
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Other: Standard of Care (SOC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Other: Standard of Care (SOC) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Standard of Care (SOC); Assigned to Arm(s): Placebo, Rivaroxaban

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study
Brief Summary: Obese patients undergoing bariatric surgery warrant VTE prophylaxis because they are at high risk for developing a fatal pulmonary embolism or postthrombotic syndrome. However, a consensus does not exist on the most effective prophylactic approach.


Options:
A: Arm Label: Group 1; Type: OTHER; Interventions: Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed | Arm Label: Group 2; Type: OTHER; Interventions: Drug: Group 2: control group with enoxaparin 40mg/d | Intervention Type: DRUG; Name: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Group 2: control group with enoxaparin 40mg/d; Assigned to Arm(s): Group 2
B: Arm Label: ENOXAPARIN 2 HOURS BEFORE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Arm Label: Enoxaparin 40 mg 12 hours before; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Intervention Type: DRUG; Name: Enoxaparin 40 mg 2 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before | Intervention Type: DRUG; Name: Enoxaparin 40 mg 12 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before
C: Arm Label: Thromboprophylaxis; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin Prefilled Syringe [Lovenox] | Intervention Type: DRUG; Name: Enoxaparin Prefilled Syringe [Lovenox]; Assigned to Arm(s): Thromboprophylaxis
D: Arm Label: Intermediate dose anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: intermediate dose Enoxaparin/ unfractionated heparin | Arm Label: Standard Prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin | Arm Label: Atorvastatin 20; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin 20mg | Arm Label: Atorvastatin 20 mg Matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched placebo | Intervention Type: DRUG; Name: intermediate dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Intermediate dose anticoagulation | Intervention Type: DRUG; Name: standard prophylactic dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Standard Prophylaxis | Intervention Type: DRUG; Name: Atorvastatin 20mg; Assigned to Arm(s): Atorvastatin 20 | Intervention Type: DRUG; Name: Matched placebo; Assigned to Arm(s): Atorvastatin 20 mg Matched placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of No Treatment Compared With Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants: a Randomized, Double-blind, Placebo-controlled, Non-inferiority Clinical Trial
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of no treatment compared with ibuprofen treatment for patent ductus arteriosus in preterm infants. The study hypothesis is that no treatment is not inferior to oral ibuprofen treatment in preterm infants. (non-inferiority study)


Options:
A: Arm Label: Paracetamol effect on ductus; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Arm Label: Paracetamol effect on pain; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain | Intervention Type: DRUG; Name: 0.45 % saline solution; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain
B: Arm Label: Oral ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ibuprofen | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Oral ibuprofen; Assigned to Arm(s): Oral ibuprofen | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Normal saline
C: Arm Label: Small ductus; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Large ductus ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Arm Label: Large ductus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Large ductus ibuprofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Large ductus placebo
D: Arm Label: early ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Early ibuprofen | Arm Label: Late Ibuprofen expectant group (placebo); Type: OTHER; Interventions: Other: Late ibuprofen expectant group (placebo) | Intervention Type: DRUG; Name: Early ibuprofen; Assigned to Arm(s): early ibuprofen | Intervention Type: OTHER; Name: Late ibuprofen expectant group (placebo); Assigned to Arm(s): Late Ibuprofen expectant group (placebo)

Answer: B